PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Technology not growing fast enough to decarbonize steel and cement industries by 2050

New study shows that for decarbonization goals of steel and cement to be met, along with new green technology, consumption habits need to change.

2023-12-11
(Press-News.org) Steel and cement are two materials that no society can do without. Their production comes with a significant carbon footprint, however. To meet zero-emission targets under the Paris Agreement, countries, cities, and industries are depending on new large-scale infrastructure for CO2 transport and storage, renewable electricity and green hydrogen. A new study by researchers at the National Institute for Environmental Studies, Japan, and the University of Cambridge, United Kingdom, shows that the current rate of deployment of this infrastructure is insufficient. The study argues that changes in how steel- and cement-based materials are used or consumed must also be considered for the Paris targets to be met.

The study, led by Dr. Takuma Watari, unveils a significant gap between anticipated and actual infrastructure deployment. For instance, scenarios made by the International Energy Agency (IEA) in 2010 estimated that nearly 200 million metric tons of CO2 from the steel and cement industries would be captured and stored by 2021. However, Watari and his colleagues found that this number was woefully off; in reality, the amount was only 1 million metric tons, which questions the 2000 million metric tons expected by the IEA to be captured and stored by 2050.

"We are not saying that the existing scenarios are physically or economically unrealistic. But simply waiting for new infrastructure to emerge and solve all our problems away is a very risky way of tackling the problem, given the scale of the challenges and the limited timeframe," said Watari.

Assuming infrastructure deployment based on historical trends and current construction plans, the study goes on to further show that the supply of steel and cement in line with carbon budgets based on the Paris Agreement will not meet demand.

"We need to be well prepared for a future shortfall between feasible supply and expected demand," noted Watari. "The construction and manufacturing industries will have to provide the same level of services with less material by changing the way products are designed, used, and disposed of."

To quantify the sense of the scale of action required, the study provides a benchmark in line with the estimated feasible supply: following Paris-compliant budgets, the same level of services with 60% less material use in construction and 40% less in manufacturing is needed.

On a positive note, the study found that the limited feasible supply at present is on pace to satisfy the basic needs of a growing world population. Indeed, the global material demand for the provision of basic needs such as electricity, water, sanitation, shelter and mobility, is far less than the estimated feasible supply.

"The challenge is more about equitable distribution than total quantity," said Watari. "We recommend a greater responsibility be placed on high-income countries, which have much larger in-use material stocks than low-income countries."

 

END


ELSE PRESS RELEASES FROM THIS DATE:

Landscape for AML patients evolving rapidly as research discoveries advance new treatments

Landscape for AML patients evolving rapidly as research discoveries advance new treatments
2023-12-11
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 10, 2023, AT 7:30 P.M. ET) – The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer.  “We’ve seen more progress during the past 10 years than the previous four decades combined,” said Justin M. Watts, M.D., Sylvester hematologist, associate professor of medicine, and Pap Corps Early Career ...

'Exceptional' results in phase III leukaemia trial

2023-12-11
University of Leeds news Embargo: 19:30 ET on Sunday 10 December 2023 / 00.30 GMT on Monday 11 December 2023 New personalised therapy improves survival for patients with CLL leukaemia Personalised treatment for the most common form of adult leukaemia helps patients survive for longer and stay in remission, a phase III trial has found. The trial, by the University of Leeds, has been identified as groundbreaking research by the New England Journal of Medicine and the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, where ...

Cell therapy appears safe and effective for lymphoma in remission

Cell therapy appears safe and effective for lymphoma in remission
2023-12-11
DOWNLOADABLE VIDEO HERE MIAMI, FLORIDA (EMBARGOED UNTIL SUNDAY, DEC. 10, 2023 AT 8:00 P.M. ET) – A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins. While the study doesn’t answer the question of whether cell therapy in remission is the right choice, it does say that it’s not the wrong choice. “I ...

ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis

2023-12-10
SAN DIEGO ― Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center. Data from the global, randomized, placebo-controlled ...

ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias

2023-12-09
SAN DIEGO ― Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations. Results from the studies were shared today in oral presentations at the 2023 American Society of Hematology (ASH) Annual Meeting. More information on all ASH Annual Meeting content from MD Anderson can be found at MDAnderson.org/ASH. Menin inhibitor monotherapy ...

ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder

ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder
2023-12-09
SAN DIEGO ― The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center. The findings, presented today at the 2023 American Society of Hematology (ASH) Annual Meeting, demonstrate that all participants treated with bezuclastinib achieved at least a 50% reduction in markers of disease burden and 63% reported their disease symptoms eased within 12 weeks. That number increased to 78% after ...

New Sylvester cancer study provides insight into underlying gene mutations in myelodysplastic syndromes

2023-12-09
EMBARGOED UNTIL DECEMBER 9, 2023, AT 12:45 P.M. ET A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms. Their findings, to be presented at ASH 2023, the American Society of Hematology’s annual meeting in Santa Diego, Dec. 9-12, could lead to development of more effective drug combinations ...

First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

2023-12-09
SAN DIEGO – Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center. The findings were published today in Molecular Cancer and presented at the 65th American Society of Hematology (ASH) Annual Meeting ...

Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL

2023-12-09
Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.  These long-term results from the S1318 clinical trial will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego on December 9 (abstract 1499). Anjali S. Advani, MD, a SWOG investigator at Cleveland Clinic Cancer Institute, led the study, with ...

Mindfulness could help women with opioid use disorder better control drug urges

2023-12-09
Mindfulness-Oriented Recovery Enhancement (MORE) — a behavioral intervention that integrates training in mindfulness, emotion regulation strategies and savoring of natural rewards — could hold the key to mitigating relapse in women undergoing medically assisted opioid use disorder treatment, a Rutgers study found.   The pilot study published in the journal Explore, is the first to evaluate the potential neural changes that underlie women’s emotion regulation and craving after an eight-week MORE intervention.   Previous studies have shown that women report higher opioid craving and show a greater inability to ...

LAST 30 PRESS RELEASES:

Inflammation may explain why women with no standard modifiable risk factors have heart attacks and strokes

Unusual carbon dioxide-rich disk detected around young star challenges planet formation models

Treetop Tutorials: Orangutans learn how to build their beds by peering at others and a lot of practice!

Scientists uncover key protein in cellular fat storage

Study finds significant health benefits from gut bugs transfer

UC Riverside pioneers way to remove private data from AI models

Total-body PET imaging takes a look at long COVID

Surgery to treat chronic sinus disease more effective than antibiotics

New online tool could revolutionize how high blood pressure is treated

Around 90% of middle-aged and older autistic adults are undiagnosed in the UK, new review finds

Robot regret: New research helps robots make safer decisions around humans

Cells ‘vomit’ waste to promote healing, mouse study reveals

Wildfire mitigation strategies can cut destruction by half, study finds

Sniffing out how neurons are made

New AI tool identifies 1,000 ‘questionable’ scientific journals

Exploring the promise of human iPSC-heart cells in understanding fentanyl abuse

Raina Biosciences unveils breakthrough generative AI platform for mRNA therapeutics featured in Science

Yellowstone’s free roaming bison drive grassland resilience

Turbulent flow in heavily polluted Tijuana River drives regional air quality risks

Revealed: Genetic shifts that helped tame horses and made them rideable

Mars’ mantle is a preserved relic of its ancient past, seismic data reveals

Variation inside and out: cell types in fruit fly metamorphosis

Mount Sinai researchers use AI and lab tests to predict genetic disease risk

When bison are room to roam, they reawaken the Yellowstone ecosystem

Mars’s interior more like Rocky Road than Millionaire’s Shortbread, scientists find

Tijuana River’s toxic water pollutes the air

Penn engineers send quantum signals with standard internet protocol

Placebo pain relief works differently across human body, study finds

New method could monitor corrosion and cracking in a nuclear reactor

Pennington Biomedical researchers find metabolic health of pregnant women may matter more than weight gain

[Press-News.org] Technology not growing fast enough to decarbonize steel and cement industries by 2050
New study shows that for decarbonization goals of steel and cement to be met, along with new green technology, consumption habits need to change.